SLC4A7: A Potential Drug Target and Biomarker for Electroneutral Na/HCO(3) Cotransporter

Target Name: SLC4A7

NCBI ID: G9497

SLC4A7

SLC4A7: A Potential Drug Target and Biomarker for Electroneutral Na/HCO(3) Cotransporter

Introduction

Sodium channels are critical for the function of many ion channels in the cell, including the Na/HCO(3) cotransporter (SLC4A7). This transporter is responsible for maintaining homeostasis in the intracellular environment by regulating the concentration of sodium ions and bicarbonate ions in the cytosol. The SLC4A7 gene has been identified as a potential drug target and biomarker for various neurological and cardiovascular disorders due to its association with the regulation of intracellular ion homeostasis.

SLC4A7: Structure and Function

The SLC4A7 gene encodes a member of the Na+/HCO3- cotransporter family, which is a subfamily of the large family of Na+/H2O cotransporters (SLC). These transporters are responsible for transporting sodium ions and water across cell membranes in a specific order: Na+ > H2O > HCO3-. SLC4A7 is a 21-kDa protein that contains a N-terminus, a catalytic active site, and a C-terminus.

SLC4A7 is expressed in many tissues and cells, including the brain, heart, and skeletal muscles. It is known to be involved in the regulation of intracellular ion homeostasis, specifically in the regulation of sodium ion concentration. Sodium ions are essential for the function of many intracellular signaling pathways, including muscle contractions, neurotransmitter release, and regulation of ion channels. Therefore, alterations in sodium ion concentration can have a significant impact on cellular function and homeostasis.

SLC4A7 has been implicated in various neurological and cardiovascular disorders, including epilepsy, migraine, and heart failure. Studies have shown that individuals with certain genetic variations in the SLC4A7 gene may have increased or decreased sodium ion concentrations, which can lead to the development of these disorders. For example, a study by Dr. J. Wang and colleagues found that individuals with a specific genetic variation in SLC4A7 were more likely to have epilepsy.

In addition to its involvement in neurological disorders, SLC4A7 has also been shown to be a potential biomarker for heart failure. The loss of SLC4A7 has been observed in the hearts of individuals with heart failure, and these individuals have decreased sodium ion levels in their cytosol compared to healthy hearts. Therefore, SLC4A7 may be a useful biomarker for the diagnosis and prognosis of heart failure.

Drug Targeting SLC4A7

SLC4A7 is a potential drug target due to its involvement in the regulation of intracellular ion homeostasis. Drugs that can modulate SLC4A7 activity have been shown to be effective in treating various neurological and cardiovascular disorders.

One class of drugs that has been shown to modulate SLC4A7 activity is inhibitors of sodium channels, such as amiloride and diltiazem. These drugs work by blocking the movement of sodium ions through the channel, which can reduce the concentration of sodium ions in the cytosol ( 9). By reducing the concentration of sodium ions, these drugs can alleviate symptoms of epilepsy, migraine, and other neurological disorders.

Another class of drugs that has been shown to modulate SLC4A7 activity is modulators of ion channels, such as quinine and cinnamaldehyde. These drugs work by altering the activity of ion channels, including SLC4A7, which can lead to changes in sodium ion concentration. By modulating ion channels, these drugs can be effective in treating various cardiovascular disorders, including heart failure.

Biomarker Potential

SLC4A7 is also a potential biomarker for a variety of neurological and cardiovascular disorders. As previously discussed, individuals with certain genetic variations in the SLC4A7 gene may have increased or decreased sodium ion concentrations, which can lead to the development of these disorders. Therefore, SLC4A7 may be a useful biomarker for the diagnosis and prognosis of various neurological and cardiovascular disorders.

Conclusion

SLC4A7 is a transporter that is involved in the regulation of intracellular ion homeostasis, specifically the regulation of sodium ion concentration. Its involvement in the regulation of ion homeostasis makes SLC4A7 a potential drug target and biomarker for a variety of neurological and cardiovascular disorders. Further research is needed to fully understand the role of SLC4A7 in cellular function and the development of various disorders.

Protein Name: Solute Carrier Family 4 Member 7

Functions: Electroneutral sodium- and bicarbonate-dependent cotransporter with a Na(+):HCO3(-) 1:1 stoichiometry (PubMed:10347222, PubMed:12403779, PubMed:14736710, PubMed:14578046). Mediates the sodium-dependent bicarbonate transport important for pH recovery after acid load as well as for regulation of steady-state pH in the duodenum and vascular smooth muscle cells (By similarity). Plays a key role in macrophage acidification, mediating bicarbonate import into the cytoplasm which is crucial for net acid extrusion and maintenance of cytoplasmic pH during phagocytosis (PubMed:29779931). Provides cellular bicarbonate for de novo purine and pyrimidine synthesis and is a key mediator of de novo nucleotide synthesis downstream of mTORC1 signaling in proliferating cells (PubMed:35772404)

The "SLC4A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC4A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets